--- title: "Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1% - Time to Sell?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296648010.md" description: "Kodiak Sciences (NASDAQ: KOD) shares dropped 4.1% to $38.20 on Friday, with trading volume significantly below average. Analysts hold mixed views: Weiss Ratings issued a 'sell' rating, while JPMorgan and Chardan Capital raised price targets and ratings to 'overweight' and 'buy', respectively. The consensus rating is 'Moderate Buy' with a target of $48.14. The company recently reported a quarterly EPS miss of ($1.05) versus estimates of ($0.96). Institutional investors, including Jane Street Group and Federated Hermes, increased their stakes in the first and second quarters." datetime: "2026-08-21T20:00:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296648010.md) - [en](https://longbridge.com/en/news/296648010.md) - [zh-HK](https://longbridge.com/zh-HK/news/296648010.md) generator: "portal-rs" --- # Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1% - Time to Sell? Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) shares dropped 4.1% during trading on Friday . The company traded as low as $38.14 and last traded at $38.20. Approximately 260,887 shares were traded during trading, a decline of 69% from the average daily volume of 847,945 shares. The stock had previously closed at $39.84. Get **Kodiak Sciences** alerts: ## Analysts Set New Price Targets A number of equities research analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Kodiak Sciences in a research report on Friday, July 10th. JPMorgan Chase & Co. raised their price objective on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Chardan Capital raised shares of Kodiak Sciences from a "neutral" rating to a "buy" rating and increased their target price for the stock from $14.00 to $61.00 in a research note on Monday, May 11th. HC Wainwright reiterated a "buy" rating and set a $58.00 price target on shares of Kodiak Sciences in a research report on Monday. Finally, Wall Street Zen downgraded shares of Kodiak Sciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $48.14. **Get Our Latest Research Report on Kodiak Sciences** ## Kodiak Sciences Price Performance The stock's 50 day simple moving average is $39.81 and its two-hundred day simple moving average is $35.45. The stock has a market capitalization of $2.40 billion, a PE ratio of -9.13 and a beta of 2.21. Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, equities research analysts predict that Kodiak Sciences Inc. will post -3.83 earnings per share for the current fiscal year. ## Institutional Investors Weigh In On Kodiak Sciences Several large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in shares of Kodiak Sciences in the first quarter worth about $188,000. Dynamic Technology Lab Private Ltd purchased a new position in Kodiak Sciences in the 1st quarter valued at approximately $94,000. Jane Street Group LLC raised its holdings in Kodiak Sciences by 441.3% during the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company's stock valued at $181,000 after acquiring an additional 52,705 shares during the period. American Century Companies Inc. lifted its position in shares of Kodiak Sciences by 6.3% during the second quarter. American Century Companies Inc. now owns 79,745 shares of the company's stock worth $297,000 after acquiring an additional 4,703 shares in the last quarter. Finally, Federated Hermes Inc. boosted its holdings in shares of Kodiak Sciences by 190.7% in the second quarter. Federated Hermes Inc. now owns 244,231 shares of the company's stock worth $911,000 after acquiring an additional 160,225 shares during the period. Hedge funds and other institutional investors own 89.06% of the company's stock. ## Kodiak Sciences Company Profile (Get Free Report) Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders. The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection. ## Featured Articles - Five stocks we like better than Kodiak Sciences - Blueprint for a Boom: SEC Clears the Crypto Runway - Ross Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss - Advance Auto Parts Plunged, But Its Turnaround Is Still Working - Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Kodiak Sciences Right Now? Before you consider Kodiak Sciences, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list. While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [KOD.US](https://longbridge.com/en/quote/KOD.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [FHI.US](https://longbridge.com/en/quote/FHI.US.md) - [ROST.US](https://longbridge.com/en/quote/ROST.US.md) - [TJX.US](https://longbridge.com/en/quote/TJX.US.md) - [AAP.US](https://longbridge.com/en/quote/AAP.US.md) - [PANW.US](https://longbridge.com/en/quote/PANW.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [3 Best Stocks With 75%+ Upside to Buy This Week, According to Analysts](https://longbridge.com/en/news/296148578.md) - [Kodiak Sciences’ Zenkuda Shows Strong Phase 3 GLOW2 Results](https://longbridge.com/en/news/280789942.md) - [Kodiak Sciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295839144.md) - [Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results | KOD Stock News](https://longbridge.com/en/news/285606116.md) - [Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference | KOD Stock News](https://longbridge.com/en/news/287977870.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**